Athersys jumps as respiratory disease treatment shows promise in early trials

Athersys

30/11/2021 12:54

** Shares of cell therapy developer  ATHX.O  jump ~20% to
$1.22, set to open at a two-week high
    ** Co says its MultiStem cell therapy was well-tolerated
among critically ill patients suffering from moderate to severe
acute respiratory distress syndrome (ARDS) in its early stage
trial   urn:newsml:reuters.com:*:nFWN2SL0KJ
    ** Shares set for best session in 10 months
    ** Co says notably higher median ICU-free and
ventilator-free days among MultiStem cell recipients compared to
placebo group; results were published in a peer-reviewed journal
Intensive Care Medicine
    ** Stock down ~42% YTD as of last close
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))